Spark Therapeutics, Inc. (NASDAQ:ONCE) – Investment analysts at William Blair decreased their Q1 2018 earnings per share estimates for shares of Spark Therapeutics in a research note issued to investors on Monday. William Blair analyst R. Prasad now expects that the biotechnology company will earn ($2.05) per share for the quarter, down from their prior estimate of ($1.99). William Blair also issued estimates for Spark Therapeutics’ Q2 2018 earnings at ($1.58) EPS, Q3 2018 earnings at ($1.12) EPS, Q4 2018 earnings at ($1.53) EPS, FY2018 earnings at ($6.27) EPS, FY2019 earnings at ($2.59) EPS and FY2020 earnings at ($0.70) EPS.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.89) EPS for the quarter, missing analysts’ consensus estimates of ($1.75) by ($0.14). Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The business had revenue of $1.48 million during the quarter, compared to analysts’ expectations of $1.33 million. During the same period in the previous year, the business earned ($1.04) earnings per share. The business’s quarterly revenue was up 14.7% on a year-over-year basis.

ILLEGAL ACTIVITY NOTICE: “Q1 2018 EPS Estimates for Spark Therapeutics, Inc. Cut by Analyst (ONCE)” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/11/01/q1-2018-eps-estimates-for-spark-therapeutics-inc-cut-by-analyst-once.html.

A number of other equities research analysts have also recently commented on ONCE. Jefferies Group LLC started coverage on shares of Spark Therapeutics in a research report on Monday, July 10th. They issued a “buy” rating and a $85.00 target price for the company. Zacks Investment Research cut shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. ValuEngine cut shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Cantor Fitzgerald set a $94.00 target price on shares of Spark Therapeutics and gave the company a “buy” rating in a research report on Monday, July 17th. Finally, Chardan Capital reiterated a “neutral” rating on shares of Spark Therapeutics in a research report on Monday, July 24th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eighteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $90.47.

Shares of Spark Therapeutics (NASDAQ:ONCE) traded down 3.09% during trading on Wednesday, hitting $78.40. 259,900 shares of the company’s stock were exchanged. The company’s market cap is $2.45 billion. Spark Therapeutics has a 12-month low of $35.07 and a 12-month high of $91.75. The company has a 50-day moving average of $85.01 and a 200-day moving average of $84.96.

In other Spark Therapeutics news, CEO Jeffrey D. Marrazzo sold 21,350 shares of the stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $80.01, for a total transaction of $1,708,213.50. Following the completion of the transaction, the chief executive officer now owns 251,350 shares of the company’s stock, valued at $20,110,513.50. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Jeffrey D. Marrazzo sold 15,000 shares of the stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $75.10, for a total transaction of $1,126,500.00. Following the transaction, the chief executive officer now directly owns 245,000 shares of the company’s stock, valued at approximately $18,399,500. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,090,850 shares of company stock valued at $91,901,774. 7.30% of the stock is currently owned by insiders.

A number of hedge funds have recently made changes to their positions in the business. Principal Financial Group Inc. boosted its stake in Spark Therapeutics by 0.3% during the first quarter. Principal Financial Group Inc. now owns 38,752 shares of the biotechnology company’s stock worth $2,067,000 after buying an additional 122 shares during the period. Cornerstone Capital Management Holdings LLC. boosted its stake in Spark Therapeutics by 3.2% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 11,089 shares of the biotechnology company’s stock worth $662,000 after buying an additional 342 shares during the period. Ameritas Investment Partners Inc. boosted its stake in Spark Therapeutics by 23.6% during the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after buying an additional 389 shares during the period. KCG Holdings Inc. boosted its stake in Spark Therapeutics by 9.4% during the first quarter. KCG Holdings Inc. now owns 6,247 shares of the biotechnology company’s stock worth $333,000 after buying an additional 538 shares during the period. Finally, Teachers Advisors LLC boosted its stake in Spark Therapeutics by 1.9% during the first quarter. Teachers Advisors LLC now owns 34,534 shares of the biotechnology company’s stock worth $1,842,000 after buying an additional 650 shares during the period. 77.29% of the stock is owned by institutional investors.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.